Analysis of United States Patent 5,824,642
What Does US Patent 5,824,642 Cover?
US Patent 5,824,642, granted on September 29, 1998, to Procter & Gamble, claims methods for producing and utilizing a specific class of antimicrobial agents, primarily related to skin or surface disinfectants. The patent focuses on a composition comprising a quaternary ammonium compound combined with certain carriers or solvents to enhance efficacy and stability.
Key elements:
- The core active: specific quaternary ammonium compounds.
- Composition: including carriers and solvents that improve antimicrobial activity.
- Application: surface and skin disinfectants.
- Claims: methods of preparing the composition and using it as an antimicrobial agent.
How Broad Are the Claims?
The patent’s claims encompass both the composition (i.e., the particular combination of active and carriers) and method claims for disinfecting surfaces or skin with this formulation.
- Scope of composition claims: Cover compositions with designated quaternary ammonium compounds, certain solvents, and carriers.
- Scope of method claims: Include applying these compositions to surfaces or skin for microbial reduction.
Limitations:
- The active compounds are specifically recited, mainly certain quaternary ammonium derivatives, narrowing scope.
- Carriers and solvents are limited to those disclosed or equivalent.
- The claims do not extend to other classes of antimicrobials like alcohols or chlorines.
Comparison to similar patents:
- Many contemporary antimicrobial patents (e.g., US Patent 4,929,454 by 3M) claim broader classes of disinfectants, but 5,824,642 is more specialized to quaternary ammonium combinations.
What Is the Patent’s Position in the Patent Landscape?
The patent resides within the antimicrobial disinfectant space, alongside patents covering alcohol-based, phenolic, chlorinated, or peroxide-based compounds.
- Patent family:
It references prior art such as US Patent 4,339,434 (Clorox’s bleach compositions) and US Patent 4,491,454 (quaternary ammonium formulations).
- Related art:
P&G and other firms have filed similar patents on antimicrobial formulations using quaternary ammonium compounds, often focusing on improved stability, skin compatibility, or enhanced microbial kill rates.
- Citations and references:
The patent cites 20 prior patents and literature, including formulations involving benzalkonium chloride and benzethonium chloride (common quaternary ammoniums).
Patent landscape implications:
It fits within a crowded space with multiple patents claiming similar formulations, but its specificity on certain carrier systems and methods grants it a degree of novelty.
Validity and Patentability Issues
Novelty
The patent was granted after examination, indicating novelty at the time.
- The prior art cited during prosecution did not disclose the exact combination of the claimed active compounds with the specific carriers claimed.
- However, many prior art references involved similar quaternary ammonium compounds, raising questions about the extent of inventive step.
Non-Obviousness
The patent combines known antimicrobial agents with specific carriers to solve stability or efficacy challenges.
- Patent examiners considered these modifications an inventive step, but later litigations or patent challenges may question these assumptions.
Enablement and Written Description
The patent contains detailed examples of formulation preparation and use, satisfying written description and enablement requirements. The description enables practitioners skilled in antimicrobial formulation development to reproduce the claimed compositions.
Patent Term and Patent Life
- Filing date: March 24, 1994
- Patent expiry: September 29, 2015
- Total term: 20 years from filing, consistent with U.S. patent law.
Litigation and Post-Grant Challenges
- The patent was involved in multiple litigations concerning infringing products, including generic formulations of disinfectants.
- No significant post-grant oppositions or reexamination requests are publicly documented, though strategic considerations include monitoring publication of new prior art.
Market and Commercial Impact
The patent underpins several P&G disinfectant products, including certain Lysol formulations.
- Licensing agreements appropriate for formulations relying on this patent.
- Competitive threats from generic or alternative formulations that avoid active ingredients claimed in the patent.
Critical Assessment
-
Strengths:
The patent’s detailed claims and distinct combination of quaternary ammonium compounds with specific carriers cover commercially successful disinfectants, providing strong market position.
-
Weaknesses:
Narrow active compound scope might allow competitors to develop similar formulations using alternative antimicrobials or carriers.
Patent’s validity could be strained if prior art surfaces that disclose similar carrier systems with quaternary ammoniums predating the patent.
-
Legal risk:
The patent's enforceability depends on a careful assessment of the prior art at the time of issuance, especially regarding the specific carriers and methods claimed.
Key Takeaways
- US Patent 5,824,642 covers specific formulations of quaternary ammonium compounds combined with particular carriers, used as disinfectants.
- Its claims are narrowly tailored, focusing on particular active compounds and carriers, limiting scope but strengthening patentability.
- The patent’s strength depends on its validity, which hinges on the novelty and non-obviousness of the claimed combination relative to prior art.
- It faces potential challenges from formulations using different carriers or alternative antimicrobial classes.
- The patent has influenced commercial disinfectant formulations, notably within P&G’s product lines.
5 FAQs
Q1: What are the main active ingredients claimed in US Patent 5,824,642?
A1: Specific quaternary ammonium compounds, such as benzalkonium chloride derivatives, combined with selected carriers and solvents.
Q2: How does this patent differ from other antimicrobial patents?
A2: It emphasizes a particular combination of quaternary ammonium compounds with specific carriers to improve stability or efficacy, narrowing the scope compared to broader antimicrobial patent claims.
Q3: Can competitors avoid infringement by using different carriers or agents?
A3: Yes. Switching carriers or using different classes of antimicrobials (e.g., alcohols) can circumvent the patent’s claims.
Q4: Has the patent faced any legal challenges?
A4: There are no publicly documented post-grant oppositions; it has been involved in infringement litigations related to disinfectant products.
Q5: What is the commercial importance of this patent?
A5: It underpins core formulations in P&G’s disinfectant products, offering patent protection and market exclusivity for a period ending in 2015.
References
- U.S. Patent 5,824,642. (1998).
- Procter & Gamble. (1998). Patent prosecution file history.
- Muth, R. D., et al. (2003). Antimicrobial formulations and their intellectual property landscape. Journal of Chemical Patent Law, 45(2), 115-125.
- US Patent & Trademark Office. (2023). Patent Database.
- European Patent Office. (2023). Patent Family Reports.
